|
Mr. Strage, 43, is a co-founder of Axonyx, Inc., a publicly traded biotechnology company (NASD: AXYX) engaged in the development of drugs to treat Alzheimer's disease. As a founding Officer and Director, he was responsible for all business aspects of the company from its inception in 1996 to its listing on the NASDAQ-NMS in January 2001, including capital formation, budgeting, human resources, infrastructure, corporate communications and investor relations. Under his direction, Axonyx acquired its intellectual property portfolio, which now includes the commercial rights to the pre-clinical research and development programs at New York University School of Medicine and the National Institute on Aging. Some of those rights were subsequently out-licensed through pharmaceutical joint-development agreements, including a major world-wide licensing agreement with Ares-Serono S.A.
| 